EVEX:NYSEEve Holding, Inc. Analysis
Data as of 2026-04-01 - not real-time
$2.54
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Eve Holding, Inc. (EVEX) sits well below its 20‑day SMA of 2.66 and the 50‑day SMA of 3.14, trading near the identified support level of 2.34 while facing a strong resistance around 3.14. The RSI of 39 hints at a modest oversold condition, yet the MACD shows a bullish histogram crossover, suggesting limited short‑term upside momentum. Volatility is elevated at over 55 % for the past 30 days and beta exceeds 1.4, underscoring a high‑beta, high‑risk profile. Fundamental metrics are weak: the company reports no revenue, negative EBITDA of roughly $224 M, and a forward PE of -3.34, while the price‑to‑book ratio sits at a lofty 7.15. Cash on hand (~$384 M) exceeds debt (~$180 M), but the debt‑to‑equity ratio of 145 % and negative free cash flow signal a tight liquidity runway. Recent earnings calls highlighted “strong liquidity” and “significant development progress,” yet also flagged “increased cash consumption” and “regulatory hurdles.” A strategic partnership in Australia to accelerate eVTOL rollout adds a positive catalyst for long‑term growth. Overall, the stock is priced in a speculative range with limited near‑term upside, high volatility, and substantial execution risk, but it retains a long‑term growth narrative tied to the emerging urban air mobility market.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical positioning below key moving averages
- Elevated volatility and high beta
- Limited cash runway despite current liquidity cushion
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Ongoing development milestones and strategic partnership in Australia
- Continued cash burn and regulatory uncertainty
- Improving liquidity metrics but high debt load
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Long‑term tailwinds for urban air mobility and eVTOL adoption
- Strategic backing from Embraer and emerging market partnerships
- Potential upside if regulatory approvals materialize and revenue ramps
Key Metrics & Analysis
Financial Health
P/E Ratio-3.3
ROE-181.08%
ROA-37.41%
Debt/Equity145.51
P/B Ratio7.2
Op. Cash Flow$-160432000
Free Cash Flow$-112215376
Industry P/E29.1
Technical Analysis
TrendBearish
RSI39.4
Support$2.34
Resistance$3.14
MA 20$2.66
MA 50$3.14
MA 200$4.45
MACDBullish
VolumeIncreasing
Fear & Greed Index77.21
Valuation
Target Price$6.89
Upside/Downside171.09%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.43
Volatility55.05%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.